Search for Stocks Search for IPO Search for Indices

Customer Portal

EMI Card

Download

Offers

BAJAJ FINSERV DIRECT LIMITED

Open Your FREE Demat Account Now!

Apply Now

Fundamentals Financials Shareholding About Company Peer Comparison Latest News FAQs

Alivus Life Sciences Ltd. Share Price

NSE

BSE

NSE : ALIVUS

BSE : 543322

Sector : Healthcare

N/A

indicator

1D

1M

3M

6M

1Y

5Y

Price Summary

Previous Close	₹1,080.80
Day's Range	₹1,077.70 - ₹1,110.00
Open	₹1,098.00
52 Week Range	₹819.00 - ₹1,225.10
Volume	53,120
Market Cap	₹0.01

Previous Close	₹1,085.70
Day's Range	₹1,078.60 - ₹1,108.85
Open	₹1,098.80
52 Week Range	₹830.00 - ₹1,224.00
Volume	2,068
Market Cap	₹0.01

Stocks Summary

Trade Value ( ₹ in Lacs)	574.12
Market Cap (₹ in Mn)	0.01
Dividend Yield(%)	0.46
Price/Earning (TTM)	24.80
TTM EPS (₹)	44.30
P/E Ratio	27.24
Book Value(₹)	4.26
PAT Margin (%)	20.26
Face Value (₹)	2.00
ROCE(%)	25.50

Trade Value ( ₹ in Lacs)	22.45
Market Cap (₹ in Mn)	0.01
Dividend Yield(%)	0.46
Price/Earning (TTM)	24.80
TTM EPS (₹)	44.30
P/E Ratio	27.24
Book Value(₹)	4.26
PAT Margin (%)	20.26
Face Value (₹)	2.00
ROCE(%)	25.50

Financials

Particulars	QTR FY (₹ in Millions)	Annual FY (₹ in Millions)
Net sales	6418.44	22832.14
Expenses	N/A	N/A
PBT	1851.47	6312.9
Operating profit	0.0	0.0
Net profit	1369.6	4708.88

Shareholding Pattern

Promoters (% Holding)

74.87%

Mutual funds (% Holding)

5.63%

Non-Institution (% Holding)

12.56%

FI/Banks/Insurance (% Holding)

0.27%

Government (% Holding)

0.00%

FII

5.30%

About Alivus Life Sciences Ltd.

Founded	2011
Managing Director	Yasir Rawjee
NSE Symbol	ALIVUS

Peer Comparision

Stocks Name	Market Cap (Cr)(₹)	Market Price (₹)	52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd.	4,42,893.24	1,824.40	1,548.00 - 1,548.00
Divi's Laboratories Ltd.	1,76,366.71	6,789.10	5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd.	1,48,240.79	4,325.20	3,102.00 - 3,102.00
Apollo Hospitals Enterprise Ltd.	1,15,309.54	8,008.45	6,696.50 - 6,696.50
Dr. Reddy's Laboratories Ltd.	1,06,009.78	1,265.10	1,148.40 - 1,148.40
Cipla Ltd.	1,04,365.52	1,330.35	1,165.70 - 1,165.70
Lupin Ltd.	1,02,690.68	2,215.45	1,836.80 - 1,836.80
Max Healthcare Institute Ltd.	99,183.27	1,025.35	903.00 - 903.00
Mankind Pharma Ltd.	98,147.87	2,415.30	1,909.70 - 1,909.70
Zydus Lifesciences Ltd.	93,655.23	940.00	835.50 - 835.50

Latest News

Mar

21

2026

EQUITY Posted on Mar 21^st 2026

Alivus Life Sciences informs about disclosure

Pursuant to regulation 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR Regulations) read with clause 20 of Para A of Part A of Schedule III of the LODR Regulations, Alivus Life Sciences has informed that the details of Intimation/Order received by the Company from Income Tax Department is enclosed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Read More

Feb

16

2026

EQUITY Posted on Feb 16^th 2026

Alivus Life Sciences informs about updates

Alivus Life Sciences has informed that on Saturday, February 14, 2026, at around 23:00 Hrs, fire broke out at the Company’s API Plant, located at Z-103/I, SEZ, Phase II, District Bharuch, Dahej - 392 130, Gujarat, India. There have been three injuries. The team at Factory, got the situation under control in one hour at around 24:00 hrs. The Company is currently investigating the root cause of the incident and assessing the extent of damage. The Company has adequate insurance coverage and in process of intimating the insurance companies. The Company is committed to ensuring the highest safety standards. Additional details as per SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated November 11, 2024, is mentioned in Annexure-A.

The above information is a part of company’s filings submitted to BSE.

Read More

May

13

2026

EQUITY Posted on May 13^th 2026

Emmessar Biotech & Nutrition informs about press release

Emmessar Biotech & Nutrition has informed that it enclosed copies of Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026 published in today’s newspapers in Free Press Journal and Nav Shakti in accordance with Regulation 47 of the Listing Regulations.

The above information is a part of company’s filings submitted to BSE.

Read More

May

13

2026

EQUITY Posted on May 13^th 2026

Zydus Lifesciences informs about update on board meeting

Zydus Lifesciences has informed that this is in furtherance of earlier intimation dated May 8, 2026, about the meeting of the Board of Zydus Lifesciences (the Company) scheduled to be held on Tuesday, May 19, 2026. In terms of Regulation 29(1)(b) and Regulation 29(2) of the Listing Regulations, the Board of the Company, at its aforesaid meeting, will also consider the proposal for buyback of fully paid-up equity shares of the Company and the matters necessary and incidental thereto, in accordance with the applicable provisions under the Companies Act, 2013, as amended, (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws. As intimated earlier, the trading window as per the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed till Thursday, May 21, 2026, and shall open for trading on and from Friday, May 22, 2026, for all the Directors and Designated Persons of the Company. The trading window shall be deemed to be closed in respect of the aforementioned buyback proposal as well, in accordance with applicable laws.

The above information is a part of company’s filings submitted to BSE.

Read More

May

13

2026

EQUITY Posted on May 13^th 2026

Indraprastha Medical Corporation informs about newspaper publication

Pursuant to Regulation 30 read with Schedule III (Part A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Indraprastha Medical Corporation has submitted copies of the public notice of the financial results, published on 13th May, 2026, in the ‘Financial Express’, all India editions, in English language and in ‘Jansatta’, Delhi edition, in Hindi language.

The above information is a part of company’s filings submitted to BSE.

Read More

Sign in to Unlock Offers!

STEP 1/2

Open Demat Account today!

Mobile Number

Enter mobile number

Frequently Asked Questions

What is the current share price of Alivus Life Sciences Ltd. ?

The current share price of Alivus Life Sciences Ltd. is ₹1,080.80 as of 2026-05-13.

What is the Market Cap of Alivus Life Sciences Ltd. Share?

The market capitalisation of Alivus Life Sciences Ltd. is ₹13,485.66 as of 2026-05-12.

What is a 1 year return for Alivus Life Sciences Ltd. ?

The 1-year return of Alivus Life Sciences Ltd. is 0.00% as of 2026-05-13.

What is the P/E Ratio of Alivus Life Sciences Ltd. Share?

The P/E ratio of Alivus Life Sciences Ltd. is 27.24 as of 2026-05-13.

What is the 52 Week High and Low of Alivus Life Sciences Ltd. ?

The 52-week high and low of Alivus Life Sciences Ltd. are ₹1,225.10 and ₹819.00, respectively, as of 2026-05-13.

View More

Disclaimer

This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.

STEP 1/2

Open a Demat Account today!

Mobile Number Enter Valid Mobile Number

Indices : Nifty 50 Nifty Bank Nifty Financial Services Nifty Next 50 Nifty Midcap 100 BSE Sensex India Vix

Stocks : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Home

Shopping

Loan Offers

My Accounts

Explore